With revenues of £296m in 2019 and a record of vigorous growth, Chiesi Ltd. is now the number one affiliate in the Chiesi group.
We work on important therapy areas, such as neonatology, organ transplantation and rare diseases, alongside our treatments for respiratory conditions, Chiesi Ltd. is poised to extend further still the contribution we make to public health in the UK.
In the UK, Chiesi has a workforce of over 400 people employed directly or indirectly with chosen partners, who are based out of our head office in Manchester, the Research and Development centre in Chippenham, and across the UK as part of our experienced field-based sales teams.
As with every part of the Chiesi group, we embrace a shared set of values and a common code of ethical conduct. This demands the highest standards of reliability, transparency, and individual accountability, in everything we do. It emphasises the importance of collaborative working, putting people first and exchanging knowledge. Implicit in all of these values is a responsible attitude to the social and environmental impact of our actions and, in this regard, Chiesi was proud to achieve the B Corp certification in June 2019. This certification recognises our commitment to use business as a force for good, strive to ensure the business decisions and actions we take are sustainable, have regard to social and environmental considerations and involve fair and equitable treatment.
It is our people who are at the heart of what we do and what we achieve. We strive to create a culture that encourages innovation and allows everyone to flourish. In a recent employee survey, 85% of our employees said “taking everything into account, this is a great place to work”. We were therefore delighted in April 2020 to be recognised as one of the UK’s Best Workplaces 2020! This award coming on the back of being certified as a UK and European Top Employer for eight consecutive years.
Chiesi Farmaceutici S.p.A. is an international, research-based, pharmaceutical company, based in Parma, Italy. With over 80 years’ experience, Chiesi is dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the field of respiratory, neonatology, transplant medicine and rare diseases. With a turnover of €1,993M, we are among the top 50 pharmaceutical companies in the world1.
The Company was founded in 1935, as a family firm. Chiesi spans the globe, employing more than 6,000 people in 27 affiliates worldwide and sells its products in more than 80 countries1.
We embrace innovation which is a constant driver to our continued success. Products wholly, or partially, developed by Chiesi account for 81% of our sales1, and our investment in Research and Development currently stands at a record €378,3M. Chiesi ‘firsts’ include the first stem cell product approved in Europe and new options for serious genetic diseases.
Chiesi Ltd. was established in 1999 with the acquisition of Trinity Pharmaceuticals (by Chiesi S.p.A), whose ethos, values and specialist expertise perfectly complemented those of the wider Chiesi group.
UK-CHI-2100512 November 2021